ABO |
P16442
|
ABO, alpha 1-3-N-acetylgalactosaminyltransferase and alpha 1-3-galactosyltransferase
|
Enzyme
|
|
0.427 |
0.885 |
61
|
54 |
TSBP1-AS1 |
|
TSBP1 and BTNL2 antisense RNA 1
|
|
|
0.638 |
0.692 |
44
|
49 |
HLA-DRB9 |
|
major histocompatibility complex, class II, DR beta 9 (pseudogene)
|
|
|
0.682 |
0.654 |
20
|
24 |
CADM3-AS1 |
|
CADM3 antisense RNA 1
|
|
|
1.000 |
0.038 |
14
|
8 |
MSH5-SAPCD1 |
|
MSH5-SAPCD1 readthrough (NMD candidate)
|
|
|
0.760 |
0.423 |
14
|
10 |
AQP4-AS1 |
|
AQP4 antisense RNA 1
|
|
|
0.751 |
0.577 |
13
|
15 |
LINC02571 |
|
long intergenic non-protein coding RNA 2571
|
|
|
0.743 |
0.500 |
12
|
12 |
ZFPM2-AS1 |
|
ZFPM2 antisense RNA 1
|
|
|
0.736 |
0.385 |
11
|
9 |
SYN2 |
Q92777
|
synapsin II
|
Cellular structure
|
|
0.653 |
0.577 |
10
|
9 |
NPHP3-ACAD11 |
|
NPHP3-ACAD11 readthrough (NMD candidate)
|
|
|
0.663 |
0.577 |
9
|
6 |
IGLV10-54 |
A0A075B6I4
|
immunoglobulin lambda variable 10-54
|
Immune response
|
|
0.890 |
0.115 |
9
|
22 |
RAB4B-EGLN2 |
|
RAB4B-EGLN2 readthrough (NMD candidate)
|
|
|
0.641 |
0.654 |
8
|
6 |
C2-AS1 |
|
C2 antisense RNA 1
|
|
|
0.821 |
0.192 |
8
|
6 |
SPON1 |
Q9HCB6
|
spondin 1
|
Extracellular structure
|
|
0.705 |
0.385 |
8
|
8 |
HPN-AS1 |
|
HPN antisense RNA 1
|
|
|
1.000 |
0.038 |
7
|
7 |
APOC4-APOC2 |
|
APOC4-APOC2 readthrough (NMD candidate)
|
|
|
0.821 |
0.308 |
7
|
5 |
APOA1-AS |
|
APOA1 antisense RNA
|
|
|
0.760 |
0.269 |
7
|
8 |
SERPINA2 |
P20848
|
serpin family A member 2 (gene/pseudogene)
|
|
|
0.861 |
0.231 |
7
|
1 |
FUT6 |
P51993
|
fucosyltransferase 6
|
Enzyme
|
|
0.695 |
0.385 |
6
|
8 |
WTAPP1 |
|
Wilms tumor 1 associated protein pseudogene 1
|
|
|
0.890 |
0.154 |
5
|
39 |
MIA-RAB4B |
|
MIA-RAB4B readthrough (NMD candidate)
|
|
|
0.821 |
0.385 |
5
|
5 |
PPT2-EGFL8 |
|
PPT2-EGFL8 readthrough (NMD candidate)
|
|
|
0.792 |
0.462 |
5
|
4 |
FPR3 |
P25089
|
formyl peptide receptor 3
|
G-protein coupled receptor
|
|
0.839 |
0.346 |
5
|
6 |
KRT18P55 |
|
keratin 18 pseudogene 55
|
|
|
0.861 |
0.077 |
5
|
2 |